188 related articles for article (PubMed ID: 18195564)
1. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Mallolas J; Pich J; Peñaranda M; Domingo P; Knobel H; Pedrol E; Gutiérrez F; Barrufet P; Peraire J; Asenjo MA; Vidal F; Gatell JM
AIDS; 2008 Jan; 22(3):377-84. PubMed ID: 18195564
[TBL] [Abstract][Full Text] [Related]
2. [The "induction-maintenance" strategy].
Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():8-11. PubMed ID: 19572438
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
5. Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
[TBL] [Abstract][Full Text] [Related]
6. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Echeverría P; Negredo E; Carosi G; Gálvez J; Gómez JL; Ocampo A; Portilla J; Prieto A; López JC; Rubio R; Mariño A; Pedrol E; Viladés C; del Arco A; Moreno A; Bravo I; López-Blazquez R; Pérez-Alvarez N; Clotet B
Antiviral Res; 2010 Feb; 85(2):403-8. PubMed ID: 19941906
[TBL] [Abstract][Full Text] [Related]
7. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Shey M; Kongnyuy EJ; Shang J; Wiysonge CS
Cochrane Database Syst Rev; 2009 Jul; (3):CD005481. PubMed ID: 19588374
[TBL] [Abstract][Full Text] [Related]
8. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
[TBL] [Abstract][Full Text] [Related]
9. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
[TBL] [Abstract][Full Text] [Related]
11. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Kumar P; DeJesus E; Huhn G; Sloan L; Small CB; Edelstein H; Felizarta F; Hao R; Ross L; Stancil B; Pappa K; Ha B;
BMC Infect Dis; 2013 Jun; 13():269. PubMed ID: 23741991
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
14. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Torriani FJ; Komarow L; Parker RA; Cotter BR; Currier JS; Dubé MP; Fichtenbaum CJ; Gerschenson M; Mitchell CK; Murphy RL; Squires K; Stein JH;
J Am Coll Cardiol; 2008 Aug; 52(7):569-76. PubMed ID: 18687253
[TBL] [Abstract][Full Text] [Related]
15. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Allavena C; Ferré V; Brunet-François C; Delfraissy JF; Lafeuillade A; Valantin MA; Bentata M; Michelet C; Poizot-Martin I; Dailly E; Launay O; Raffi F;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):300-6. PubMed ID: 15980689
[TBL] [Abstract][Full Text] [Related]
17. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Hsu A; Isaacson J; Brun S; Bernstein B; Lam W; Bertz R; Foit C; Rynkiewicz K; Richards B; King M; Rode R; Kempf DJ; Granneman GR; Sun E
Antimicrob Agents Chemother; 2003 Jan; 47(1):350-9. PubMed ID: 12499212
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
